Driving Preclinical Assets Market Growth in 2025: The Role of Increasing Drug Discovery

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

Preclinical Assets Market Size Growth Forecast: What to Expect by 2025?
The market size for preclinical assets has seen robust growth in the past few years. The market, valued at $5.87 billion in 2024, is projected to swell to $6.4 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 9.1%. This growth trend during the historical period is credited to factors such as the increasing necessity for drug development, breakthroughs in biotechnology, obligations put forth by regulatory bodies, growth in research funding, and cooperative efforts in research.

How Will the Preclinical Assets Market Size Evolve and Grow by 2029?
The size of the preclinical assets market is projected to witness substantial growth in the upcoming years, rising to $9.3 billion in 2029 with a compound annual growth rate (CAGR) of 9.8%. The anticipated growth in this period can be credited to precision medicine and personalized therapies, the integration of ai and machine learning, the expansion of biobanking, focus on rare diseases, along with government initiatives and funding. Prominent trends expected during this forecast period encompass the rise of advanced imaging techniques, developments in 3D organoid models, the incorporation of multi-omics, improved predictive models, and the increase in automation and high throughput screening.

View the full report here:
https://www.thebusinessresearchcompany.com/report/preclinical-assets-global-market-report

What Drivers Are Propelling the Growth of Preclinical Assets Market Forward?
The preclinical asset market's expansion is predicted to be fueled by the acceleration of drug discovery. This pertains to the identification of chemical compounds that could potentially serve as medicinal agents. New potential medications are identified through this process. Within this procedure, preclinical assets are crucial as they provide the necessary data and insights to assist in the selection of molecules for clinical development. For example, the European Federation of Pharmaceutical Industries and Associations (EFPIA), a Belgium-based organization representing the pharmaceutical industry, reported in June 2023 that European pharmaceutical production experienced significant growth, increasing to $369.95 billion in 2022, up from $352.48 billion in 2021. Consequently, the upsurge in drug discovery is fuelling the development of the preclinical assets market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12600&type=smp

Which Emerging Trends Are Transforming the Preclinical Assets Market in 2025?
The rise of product innovations is a prominent trend in the preclinical assets market. Companies in this market are focusing on introducing new products and solutions to solidify their market standing and acquire a competitive edge. For example, in April 2022, US-based pharmaceutical firm Charles River Laboratories International, renowned for its preclinical and clinical lab services, teamed up with Valo Health Inc., a US technological company aiming to revolutionize drug discovery. Together, they introduced Logica, an AI-driven drug solution that converts client's biological findings into optimized preclinical assets. Logica harnesses the power of Charles River's exceptional preclinical expertise and Valo's AI-fuelled Opal Computational Platform. This partnership aims to redefine drug discovery by offering a seamlessly integrated offering that easily translates targets into candidate nomination. Charles River's alliance with Valo ties its lab proficiency with molecular design technology, transforming the industry to deliver highly credible leads and candidates to their clients, effectively linking clients' expenses to value generation.

What Are the Key Segments in the Preclinical Assets Market?
The preclinical assets market covered in this report is segmented -

1) By Service: Bioanalysis And DMPK (Drug Metabolism And Pharmacokinetic) Studies, Toxicology Testing, Compound Management, Safety Pharmacology, Other Services
2) By Model Type: Patient Derived Organoid (PDO) Model, Patient Derived Xenograft Model
3) By End User: Biopharmaceutical Companies, Government Institutes, Other End-Users

Subsegments:
1) By Bioanalysis And DMPK (Drug Metabolism And Pharmacokinetic) Studies: Pharmacokinetics (PK) Studies, Pharmacodynamics (PD) Studies, Bioanalytical Method Development
2) By Toxicology Testing: Acute Toxicity Testing, Chronic Toxicity Testing, Genotoxicity Testing, Carcinogenicity Testing
3) By Compound Management: Compound Library Management, Sample Storage And Retrieval, High-Throughput Screening Support
4) By Safety Pharmacology: Cardiovascular Safety Assessments, Neurotoxicity Evaluations, Respiratory Safety Evaluations
5) By Other Services: Regulatory Support, Preclinical Study Design And Consulting, Custom Assay Development

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=12600&type=smp

Who Are the Key Players Shaping the Preclinical Assets Market's Competitive Landscape?
Major companies operating in the preclinical assets market include Laboratory Corporation of America, IQVIA Inc., ICON PLC, Eurofins Scientific SE, PPD Inc., SGS SA, WuXi AppTec Co. Ltd., Intertrek Group PLC, Charles River Laboratories International Inc., Medpace Inc., Pharmaron Beijing Co. Ltd., Evotec SE, GenScript Biotech Corporation, Inotiv Inc., SRI International Inc., Shanghai Medicilon Inc., Biocytogen Pharmaceuticals Beijing Co. Ltd., AmplifyBio LLC, BioReliance Corporation, Pharmalegacy Laboratories Co. Ltd., Precigen Inc., ReproCELL Incorporated, InSphero AG, Crown Bioscience Inc., Comparative Biosciences Inc., TCG Lifesciences Pvt. Ltd., InVivo Biosystems, Pharmatest Services Ltd, Domainex Limited, Viroclinics Xplore

What Geographic Markets Are Powering Growth in the Preclinical Assets Market?
North America was the largest region in the preclinical assets market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the preclinical assets market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12600

This Report Supports:
1. Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2. Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3. Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4. Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.